Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Status:
RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
Angioimmunoblastic T cell lymphoma (AITL) is a rare and aggressive lymphoma. Some patients relapsed after initial treatment or did not respond to standard treatment (refractory). Subsequent treatment options are limited and the efficacy is not ideal. This study attempts to explore the possibility of improving the efficacy of immunotherapy combined with chemotherapy and epigenetic regulatory drugs.
Phase:
PHASE2
Details
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University